إعلان
إعلان

XFOR

XFOR logo

X4 Pharmaceuticals, Inc. Common Stock

3.97
USD
برعاية
+0.13
+3.41%
٠٦ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

3.97

0.00
-0.03%

تقارير أرباح XFOR

النسبة الإيجابية المفاجئة

XFOR تفوق 17 من 31 آخر التقديرات.

55%

التقرير التالي

بيانات التقرير القادم
٢٣ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$1.77M
/
-$0.38
التغير الضمني من Q3 25 (Revenue/ EPS)
+0.15%
/
-44.93%
التغير الضمني من Q4 24 (Revenue/ EPS)
+23.27%
/
-93.67%

X4 Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On ٠٥ نوفمبر ٢٠٢٥, XFOR reported earnings of -0.69 USD per share (EPS) for Q3 25, beating the estimate of -0.93 USD, resulting in a 26.15% surprise. Revenue reached 1.76 مليون, compared to an expected 2.08 مليون, with a -15.25% difference. The market reacted with a -10.58% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 المحللين forecast an EPS of -0.38 USD, with revenue projected to reach 1.77 مليون USD, implying an نقصان of -44.93% EPS, and زيادة of 0.15% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
For Q3 2025, X4 Pharmaceuticals, Inc. Common Stock reported EPS of -$0.69, beating estimates by 26.15%, and revenue of $1.76M, -15.25% below expectations.
The stock price moved down -10.58%, changed from $3.97 before the earnings release to $3.55 the day after.
The next earning report is scheduled for ٢٣ مارس ٢٠٢٦.
Based on 6 المحللين, X4 Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of $1.77M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان